Literature DB >> 33372876

Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma.

Geet Madhukar1, Naidu Subbarao1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) continues to be a global public health burden even after a tremendous development in its treatment. It is a heterogeneous cancer of upper aero-digestive tract. The contemporary strategy to treat cancer is the use of anticancer drugs against proteins possessing abnormal expression. Targeted chemotherapy was found successful in HNSCC, but, there is still a stagnant improvement in the survival rates and high recurrence rates due to undesirable chemotherapy reactions, non-specificity of drugs, resistance against drugs and drug toxicity on non-cancerous tissues and cells. Various extensive studies lead to the identification of drug targets capable to treat HNSCC effectively. The current review article gives an insight into these promising anticancer targets along with knowledge of drugs under various phases of development. In addition, new potential targets that are not yet explored against HNSCC are also described. We believe that exploring and developing drugs against these targets might prove beneficial in treating HNSCC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  EGFR; HNSCC,; MEK1; PIK3CA; RAC1; S6K2; drug target

Mesh:

Substances:

Year:  2021        PMID: 33372876     DOI: 10.2174/1568009620666201229120332

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  2 in total

1.  Identification of potent and novel inhibitors against RAC1: a Rho family GTPase.

Authors:  Geet Madhukar; Naidu Subbarao
Journal:  In Silico Pharmacol       Date:  2022-08-01

2.  High SQLE Expression and Gene Amplification Correlates with Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Lijun Fang; Weixian Liu; Yang Liu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.